首页 | 本学科首页   官方微博 | 高级检索  
     


Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial
Authors:Cees J. Tack MD  Stephan Jacob MD  Cyrus Desouza MBBS  Stephen C. Bain MD  John B. Buse PhD  Michael A. Nauck MD  John R. Petrie PhD  Neil R. Poulter FMedSci  Richard E. Pratley MD  Helen Vanya B. K. Stegmann MS  Heidrun Bosch-Traberg MD  Elena Startseva MD  Bernard Zinman MD  the LEADER Publication Committee on behalf of the LEADER Trial Investigators
Affiliation:1. Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands;2. Praxis für Prävention und Therapie, Kardio Metabolisches Institut, Villingen-Schwenningen, Germany;3. Veterans Affairs Medical Center, Omaha, Nebraska;4. Swansea University Medical School, Swansea, UK;5. University of North Carolina School of Medicine, Chapel Hill, North Carolina;6. Diabetes Center Bochum-Hattingen, St Josef Hospital (Ruhr-Universität Bochum), Bochum, Germany;7. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK;8. International Centre for Circulatory Health, Imperial College London, London, UK;9. AdventHealth Translational Research Institute, Orlando, Florida;10. Novo Nordisk A/S, Søborg, Denmark;11. Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada
Abstract:
Keywords:glucagon-like peptide-1 analogue  insulin analogues  insulin therapy  liraglutide  type 2 diabetes
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号